Heart and Cardiovascular # Three years after the Semaglutide publication 3 and the SUSTAIN 1 Study results, the SELECT Study was launched
Statements Data availability statement The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher
The case of GLP-1 illustrates how numerous inventions were needed before we arrived at a medicine that induces double-digit per cent weight loss as well as reduced cardiovascular disease risk in obesity
10.1158/1535-7163.MCT-11-0942 92 KaurH.KumarB.ChakrabartiA.MedhiB.ModiM.RadotraB
This is an imprecise measurement, but its currently the one often employed by medical providers
If you're not quite ready to dive into the Bridge but still interested in GLP-1 treatment, Mochi is here to help you access medications affordably right now, before the Bridge even launches